Hypertrophic Osteoarthropathy – Causes and Treatment
Hypertrophic osteoarthropathy is a condition characterized by clubbing of the fingers, watch-glass nails, and new bone formation along the long bones, often linked to an underlying disease.
Things worth knowing about "Hypertrophic Osteoarthropathy"
Hypertrophic osteoarthropathy is a condition characterized by clubbing of the fingers, watch-glass nails, and new bone formation along the long bones, often linked to an underlying disease.
What is Hypertrophic Osteoarthropathy?
Hypertrophic osteoarthropathy (HOA) is a clinical syndrome defined by a characteristic triad: digital clubbing (bulbous enlargement of the fingertips), watch-glass nails (abnormally curved nails), and periosteal new bone formation along the distal ends of the long bones. Arthritis (joint inflammation) may also be present. HOA most commonly occurs as a manifestation of an underlying disease and is then classified as secondary HOA. A rare, independent primary form also exists.
Forms of Hypertrophic Osteoarthropathy
Primary Hypertrophic Osteoarthropathy
The primary form, also known as pachydermoperiostosis, is a rare, genetically determined disorder. It predominantly affects males during puberty and is characterized by skin thickening (pachydermia), especially on the face and scalp, along with periostosis and digital clubbing. Mutations in the HPGD and SLCO2A1 genes, which regulate prostaglandin E2 metabolism, have been identified as the underlying cause.
Secondary Hypertrophic Osteoarthropathy
Secondary HOA is far more common and develops as a consequence of an underlying condition. It is most frequently associated with pulmonary diseases but may also be linked to cardiac, hepatic, and other systemic disorders.
Causes and Underlying Conditions
Secondary HOA is most commonly associated with lung disease. The most frequent causes include:
- Lung tumors (especially non-small cell lung carcinoma) – the most common cause in adults
- Chronic lung diseases (e.g., bronchiectasis, cystic fibrosis, lung abscess)
- Congenital cyanotic heart defects
- Infective endocarditis
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Liver diseases (e.g., liver cirrhosis, primary biliary cholangitis)
- Mesothelioma and other intrathoracic tumors
The pathophysiological mechanisms are thought to involve increased secretion of growth factors such as VEGF (Vascular Endothelial Growth Factor) and dysregulation of prostaglandin E2, leading to periosteal proliferation and tissue overgrowth.
Symptoms
The clinical features of HOA include:
- Digital clubbing and watch-glass nails: Painless, bulbous enlargement of the fingertips with abnormally curved nails
- Periostosis: Bone pain, particularly in the lower legs, forearms, wrists, and ankles, caused by periosteal new bone formation
- Arthritis: Joint swelling and pain, especially affecting large joints such as the knees, ankles, and wrists
- In primary HOA: thickening of facial skin, sebaceous gland hyperplasia, and increased sweating
Diagnosis
Diagnosis of HOA is based on clinical examination combined with imaging and laboratory investigations:
- X-rays: Reveal characteristic periosteal new bone formation along the long bones
- Bone scintigraphy: Shows increased tracer uptake along the diaphyses (bone shafts) as an early diagnostic finding
- MRI and CT: Used to assess soft tissue changes and to identify the underlying cause
- Laboratory tests: Elevated inflammatory markers (CRP, ESR); VEGF levels may be elevated
- Workup for underlying disease: Chest CT, echocardiography, endoscopy, and other targeted investigations
Treatment
The management of secondary HOA is primarily directed at treating the underlying disease. Successful treatment of the cause can lead to regression of HOA symptoms.
Symptomatic Treatment
- Nonsteroidal anti-inflammatory drugs (NSAIDs): For relief of pain and joint inflammation
- Bisphosphonates (e.g., pamidronate, zoledronate): Inhibit bone remodeling and reduce pain
- COX-2 inhibitors: May be effective in primary HOA (pachydermoperiostosis) by inhibiting prostaglandin synthesis
- Octreotide: A somatostatin analogue used in selected cases
- In primary HOA: retinoid therapy for skin manifestations
References
- Martinez-Lavin M. - Hypertrophic Osteoarthropathy: Its Importance in Daily Clinical Practice. - Reumatologia Clinica, 2011.
- Uppal S, Diggle CP, Carr IM et al. - Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. - Nature Genetics, 2008.
- Pineda C, Fonseca C, Martinez-Lavin M. - The spectrum of soft tissue and skeletal abnormalities of hypertrophic osteoarthropathy. - Journal of Rheumatology, 1990.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryChlorine dioxide
Calorie expenditure
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Hypertrophic Osteoarthropathy-en